Abstract
This report summarizes our experimental data concerning the use of bispecific antibodies (bsAb) for the treatment of the murine BCL1 B cell lymphoma model. Initially we used a hybrid-hybridoma-derived bsAb with specificity for the TcR/CD3 complex on T cells and the idiotype of the membrane-bound IgM on the tumor cells. The bsAb used as a single agent could cure animals with a low tumor load (resembling minimal residual disease). However, in experiments aimed at increasing the therapeutic effect in animals with a higher tumor burden, we could demonstrate the importance of additional T-cell-costimulatory signals and the careful timing of the bsAb administration. Recently we have generated a bispecific single-chain Fv (bsscFv) fusion protein with the same dual specificity as the hybrid-hybridoma-derived bsAb. Immunotherapy with this smaller molecule also resulted in tumor elimination in BCL1-bearing mice. A second bsscFv (α-CDl9×α-CD3) with a broader applicability is now being characterized and tested in vivo.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Accepted: 14 October 1997
Rights and permissions
About this article
Cite this article
De Jonge, J., Heirman, C., De Veerman, M. et al. Bispecific antibody treatment of murine B cell lymphoma. Cancer Immunol Immunother 45, 162–165 (1997). https://doi.org/10.1007/s002620050423
Issue Date:
DOI: https://doi.org/10.1007/s002620050423